USO DA RETATRUTIDA NO TRATAMENTO DA ESTEATOSE HEPÁTICA E OBESIDADE: REVISÃO INTEGRATIVA
LUMEN ET VIRTUS · 09.07.2026 · 17 (62) · e13743
DOI: 10.56238/levv17n62-013 ↗Kurz gefasst
Fachartikel in der Zeitschrift LUMEN ET VIRTUS, online erschienen am 09.07.2026. Verfasst von Gabriela Vitória dos Santos und 23 weiteren Autor:innen.
Abstract (Originalsprache)
Obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) are major global public health challenges, being associated with increased morbidity, mortality, and healthcare costs. In this context, novel pharmacological therapies have been developed to promote significant weight reduction and improve metabolic and hepatic outcomes. Retatrutide, a triple agonist of the GLP-1, GIP, and glucagon receptors, has emerged as an innovative therapeutic approach due to its ability to simultaneously target multiple pathways involved in energy metabolism regulation. The aim of this study was to analyze the available scientific evidence regarding the use of retatrutide in the treatment of obesity and MASLD. This integrative literature review included studies published between 2016 and 2026, identified through searches in the MEDLINE/PubMed and ScienceDirect databases. Clinical trials, prospective studies, systematic reviews, and relevant publications addressing the topic were included. The analyzed evidence demonstrated that retatrutide promotes weight reductions exceeding 24%, in addition to significant improvements in metabolic, glycemic, and cardiovascular parameters. In patients with MASLD, substantial reductions in liver fat content, exceeding 80% at higher doses, were observed, along with high rates of normalization of hepatic fat levels. Compared with previously established incretin-based therapies, such as semaglutide and tirzepatide, retatrutide showed particularly promising results. In conclusion, retatrutide represents one of the most innovative pharmacological approaches currently under development for the treatment of obesity and MASLD, although long-term studies are still required to confirm its sustained efficacy and clinical safety.
Zitieren
APA
Santos, G. V. D., Nascimento, E. D. S. R. D., Carvalho, R. O. V., Teixeira, M. S., Bezerra, P. T. M., Vieira, L. H. S., Bezerra, I. P., Salvadego, M. A. L. D. O., Alexandre, B. G. F., Nascimento, S. B. D., Nascimento, S. L. D. O. R., Moura, M., Bastos, F. D. O., Siqueira, A. L. D., Machado, F. M., Silva, I. P. E., Oliveira, A. C. G. D., Beltrão, C. A. M. D. S., Amestoy, H. B., …, & Reis, T. D. S. O. (2026). USO DA RETATRUTIDA NO TRATAMENTO DA ESTEATOSE HEPÁTICA E OBESIDADE: REVISÃO INTEGRATIVA. LUMEN ET VIRTUS, 17(62), e13743. https://doi.org/10.56238/levv17n62-013
Vancouver
Santos GVD, Nascimento EDSRD, Carvalho ROV, Teixeira MS, Bezerra PTM, Vieira LHS, et al. USO DA RETATRUTIDA NO TRATAMENTO DA ESTEATOSE HEPÁTICA E OBESIDADE: REVISÃO INTEGRATIVA. LUMEN ET VIRTUS. 2026;17(62):e13743. doi:10.56238/levv17n62-013
BibTeX
@article{Santos2026,
author = {Santos, Gabriela Vitória dos and Nascimento, Eberson da Silva Rodrigues do and Carvalho, Rafaela Oliveira Vidal and Teixeira, Miguel Siqueira and Bezerra, Paulo Tiago Moura and Vieira, Luís Henrique Santiago and Bezerra, Iza Pereira and Salvadego, Matheus Alvino Liutti de Oliveira and Alexandre, Bruna Gabriela Frizzo and Nascimento, Silas Basílio do and Nascimento, Saile Lucyanne de Oliveira Ruy and Moura, Marina and Bastos, Flávio de Oliveira and Siqueira, Amanda Lobo de and Machado, Felipe Mendes and Silva, Igor Paolinelli e and Oliveira, Amanda Carolina Galvão de and Beltrão, Carlos Arthur Marinho da Silva and Amestoy, Hélio Bordoli and Almeida, Renata Karam de and Grando, Vitória Gabriela and Neves, Tamilis de Azevedo and Neri, Diegomaier Nunes and Reis, Tatiane da Silva Oliveira},
title = {USO DA RETATRUTIDA NO TRATAMENTO DA ESTEATOSE HEPÁTICA E OBESIDADE: REVISÃO INTEGRATIVA},
journal = {LUMEN ET VIRTUS},
year = {2026},
volume = {17},
number = {62},
pages = {e13743},
doi = {10.56238/levv17n62-013}
}
EUVIMED